KLRG1 antagonist signaling therapy

US11339222B2 · kind B2 · utility

Assignee

• The Brigham and Women's Hospital, Inc. · US

Inventors

• Steven A. Greenberg · Newton, US
• Stefano V. Gulla · Boston, US
• Kenneth Evan Thompson · Avon Park, US

Key dates

• Filing date: Jun 2, 2017
• Grant date: May 24, 2022
• Expiry date: Nov 21, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/531
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.